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Background: The association between infertility treatments and mental disorders has
been poorly addressed. This work aims to review current evidence on the
psychopathological effects of hormonal treatments used for infertility on women and the
occurrence of newly diagnosed mood and psychotic disorders.
Methods: A systematic review was performed by searching PubMed and clinicaltrials.gov
databases from inception until September 2019. Clinical trials on hormone treatments for
infertility in patients with mood or psychotic disorders, as well as those evaluating the
onset of symptoms, were included. Selected studies were published in English, Spanish,
and Dutch language peer-reviewed journals. Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines were followed. Observational studies
and case reports were excluded. Effect sizes for changes in depressive symptoms were
calculated with Hedges’g and Cohen’s d confidence intervals. A meta-analysis was not
performed due to the heterogeneity of hormonal compounds in protocols.
Results: From 1,281 retrieved records, nine trials were included; all of them were
conducted in non-clinical populations. Four trials compared Gonadotropin-releasing
hormone (GnRH) agonists and GnRH antagonists, showing a better mood profile for
hormonal protocols including antagonists in one trial. Two trials compared protocols using
GnRH agonists/antagonists versus natural cycle protocols (without gonadotropin
stimulation), with a better mood profile (less depressive symptoms) in those protocolsg May 2020 | Volume 11 | Article 4791
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Frontiers in Psychiatry | www.frontiersin.orwithout gonadotropin stimulation. Other studies compared long and short protocols of
GnRH agonists (no differences); two GnRH agonists, buserelin, and goserelin (no
differences); and two patterns of clomiphene vs placebo administration (no differences).
None of the selected studies investigated the risk of relapse in women with a previous
diagnosis of depressive or psychotic disorders. When exploring pre-post changes in
depressive symptoms, effect sizes suggested mild mood worsenings for most protocols
(effect sizes ≤ -0.4), with the following pattern (worse to better): GnRH agonist > GnRH
antagonist > no gonadotropin stimulation.
Conclusions: This is the first systematic review exploring the psychopathological effects
of hormonal infertility treatments. Our study suggests that protocols without gonadotropin
stimulation show a better mood profile when compared to those using GnRH antagonists
or GnRH agonists. Future studies need to include patients with major mood and psychotic
disorders.Keywords: infertility, sex hormones, fertility treatments, psychosis, affectiveINTRODUCTION
Women with fertility problems have been extensively found to
suffer from psychological burden and may experience this
clinical situation as very stressful (1). The relationship between
assisted reproductive technologies (ARTs) and mental distress is
complex, and it calls for a careful examination of the direction of
the effects between both variables (2–4).
ART treatments may increase mental distress in women
undergoing these therapeutic options (1). Mental health
consequences may be partially explained by psychological
factors, such as neuroticism, as well as by biological factors
derived from the biochemical nature of treatment compounds (3).
When focusing on reproductive medicine, it seems to be
crucial to determine whether a woman is infertile (5). Medical
history (e.g., health history, the use of other medications);
physical examination; blood tests including assessments of
hormone levels; and ultrasonography exploring the ovaries,
uterus and Fallopian tubes appear to be mandatory (5, 6). In
some cases, infertility in women might be secondary to an
ovulation problem or an obstruction of the Fallopian tubes (7).
However, in 5%–15% of cases, all tests and physical examinations
are normal, and specific causes cannot be determined (8).
Once the cause of infertility is found, all potential options for
treatment should be considered (9). Briefly, four main types of
infertility treatment are available: gamete intrafallopian transfer
(GIFT) and zygote intrafallopian transfer (ZIFT), intrauterine
insemination (IUI), and in vitro fertilization (IVF) techniques
(10). IUI is a fertility treatment based on placing sperm directly
into the uterus while the woman is ovulating (11). IVF is an ART
process based on controlled ovarian stimulation, egg retrieval from
women’s ovaries and the fertilization of these eggs with sperm in
the laboratory (11). Finally, the embryo is placed in the woman’s
uterus. GIFT and ZIFT refer to the collection and placement of
gametes or zygotes, respectively, into the Fallopian tube (12).
Regarding IVF techniques, we will focus on the use of
biological compounds, mainly hormones, aiming to achieveg 2controlled ovarian stimulation. These molecules are factors
that can be associated with psychopathological changes in
healthy women and women with previous mental disorders (9).
Many biological compounds have been developed for
ovulation induction in IVF, with the main aim of obtaining
more oocytes (13), including clomiphene citrate, aromatase
inhibitors, gonadotrophins, and gonadotropin-releasing
hormone (GnRH) analogues (9). Clomiphene citrate blocks
oestrogen receptors and increases follicle-stimulating hormone
(FSH) levels. Aromatase inhibitors block the conversion of
androgens to oestrogens. Gonadotrophins include recombinant
FSH and luteinizing hormone (LH), and GnRH analogues
include agonists and antagonists.
Conventional controlled ovarian stimulation protocols
include the administration of gonadotropin-releasing hormone
(GnRH) agonists with the main aim of the desensitization of the
pituitary gland through the suppression of the release of both
pituitary follicle-stimulating hormone (FSH) and luteinizing
hormone (LH) (13). This technique has been successfully
associated with IVF; however, several adverse effects have also
been described, such as mood disturbances (3). More recently,
GnRH antagonist protocols have been found to be an alternative
for ovarian stimulation. They seem to show lower rates of
ovarian hyperstimulation syndrome and may reduce the length
of ovulatory stimuli compared with other ovulation induction
protocols (14). GnRH antagonist protocols are based on the daily
administration of recombinant follicle stimulating hormone (r-
FSH) analogue to start ovarian stimulation (2–3 cycle days).
Some studies have found GnRH protocols to have higher rates of
pregnancies than treatment with clomiphene or aromatase
inhibitors (13). More recently, a short GnRH antagonist
protocol has been recommended for younger women
undergoing their first ART cycle (14).
Nevertheless, sex hormones have been found to regulate
mood and may play an important role on the pathophysiology
of affective disorders as well as schizophrenia and other psychotic
disorders (15). Rubinow and Schmidt proposed several models toMay 2020 | Volume 11 | Article 479
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hormonal effects and how the regulation of affect may be sex
dependent (16). These investigations have also been conducted
in patients with psychotic disorders. If the response to stress may
be dysregulated in psychosis, Goldstein and co-workers (17)
reported that the interplay between steroid hormones and neural
activity may be sex dependent in psychosis, particularly for brain
functions implicating the prefrontal cortex (17, 18).
In the particular case of GnRH agonists, it should be noted
that they combine hormonal control of the cycle by means of a
hypoestrogenism state. This short induced-hormonal state may
determine subsequent mental health consequences that may be
partially explained through the hypothalamic-pituitary-gonadal
axis (19). Hormonal changes and withdrawal of oestrogens may
determine an increased vulnerability to depression in women as
well as a poorer prognosis (worsening of psychotic symptoms,
greater risk of relapse and higher needs of antipsychotic dosages)
in female patients with schizophrenia (20, 21). Therefore, those
fertility treatments that induce hypoestrogenism may have a
negative effect on depressive or psychotic symptoms.
Although some studies have addressed the effects of sex
steroids in brain functions in individuals with and without
mental illnesses (15–18), no previous systematic reviews have
explored the effects of infertility hormonal treatments on
psychopathology in women. The vast majority of the studies
have investigated pregnancy outcomes or other somatic
concerns, and psychopathological symptoms have been
widely neglected.
Several observational studies have investigated the prevalence
rates for psychiatric disorders in women undergoing fertility
treatments (22). The authors found a prevalence of mood
disorders around 26% in women, highlighting that major
depression was the most common diagnosis. In contrast with
these findings, Salih Joelsson et al. (23) compared depressive
symptoms in pregnant and non-pregnant women, and
pregnant women receiving fertility treatment (23). Pregnant
women did not differ in depressive symptoms compared to the
other two groups, suggesting a lack of negative effect of fertility
treatments on psychopathological symptoms. More recently,
Freeman et al. (24) carried out a prospective observational
study in women with a previous history of unipolar or bipolar
depression undergoing fertility treatment (24). They concluded
that maintenance of psychotropic medication was not sufficient
for avoiding affective recurrences. With regard to schizophrenia
and other psychoses, a national register study compared the
success rates of fertility in women with and without psychotic
disorders (25), although exacerbation of psychotic symptoms
was not investigated.
In brief, findings from cohort and observational studies seem
to be contradictory and inconclusive. Therefore, we aimed to
systematically review current evidence on the psychopathological
effects of hormonal treatments for infertility on women and the
influence of these treatments on the occurrence of newly
diagnosed mental disorders. We focused mainly on
investigations concerning women with mood disorders and
psychotic disorders.Frontiers in Psychiatry | www.frontiersin.org 3METHODS
Search Strategy
A systematic computerized search was performed by focusing on
trials evaluating the effect of hormone treatments for infertility in
major depression, bipolar disorder, schizophrenia, and other
psychotic disorders. PubMed database and ClinicalTrials.gov
were searched from inception until September 2019 in keeping
with the Preferred Reporting Items for Systematic Reviews and
Meta-analyses (PRISMA) guidelines (26). Electronic search was
also completed by revising all references of including studies for
potential papers to be included.
The following search terms were used: (clomiphene OR GnRH
OR letrozole OR vorozole OR anastrozole OR aromatase
inhibitors OR FSH OR LH OR r-FSH OR r-LH OR in vitro
fertilization OR IVFOR ICSI OR intracytoplasmic sperm injection
OR ovarian stimulation OR controlled ovarian hyperstimulation)
AND (psychiatric OR psychopathology OR psychopathological
OR relapse OR recurrence OR depression OR bipolar OR mania
OR psychosis OR schizophrenia) AND trial.
Inclusion Criteria
Studies that met the following inclusion criteria were considered:
a) trials focused on evaluating the effect of hormonal treatment for
infertility on women; b) studies that evaluated psychopathological
effects of infertility treatments on women without a diagnosis of
mental disorders (newly diagnosed mental disorder) or in women
with a previous mental disorder (major depression, bipolar
disorder, schizophrenia and other psychotic disorders);
c) published trials in peer-reviewed journals or registered in
clinicaltrials.gov; d) articles written in English, Spanish or Dutch
language; and e) studies that assessed the effectiveness of hormone
compounds for the treatment of infertility.
The exclusion criteria were as follows: a) naturalistic studies
and case reports, b) studies assessing the effect of hormone
compounds administered for uses other than the treatment of
infertility, and c) studies exploring the effectiveness of hormone
drugs to treat mental disorders.
Data Collection and Extraction
Titles and abstracts of studies identified in the initial searches
were screened independently by two review authors (AG-R and
JC). The same authors extracted data independently. Any
disagreements or discrepancies between them were resolved by
consensus and were explored with a third additional reviewer.
Full-text documents were also reviewed. From the initially
selected articles, those that did not meet our inclusion criteria
or met any exclusion criterion were excluded. The last search was
conducted on 29th October 2019. The PICO method for the
systematic review is detailed in Table S1.
Risk of Bias
The risk of bias was evaluated using the Cochrane risk of bias tool.
Studies were classified into three categories attending to their
quality: good, fair, and poor. A meta-analysis was not performed
due to the heterogeneity of the hormonal treatment protocols.May 2020 | Volume 11 | Article 479
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Symptoms
For those clinical trials that included information on depressive
symptoms at baseline and after the hormonal treatment for
infertility, effect sizes were calculated. Hedges’ g was used as a
measure of the effect size for changes in depressive symptoms
after the hormonal protocol using an on-line calculator that
allows the calculation of the effect size for paired samples tests
(https://effect-size-calculator.herokuapp.com/#paired-samples-
t-test). Another effect size measure considered in the systematic
review was confidence intervals (lower and upper limits) using
Cohen’s d. These measures were calculated using pre-post scores
(depressive symptoms) and standard deviation measures of all
studies with available data. If data were available as the median
(interquartile range), the mean and SD were estimated as
described previously (27). In a few cases in which data were
only available in figures, we extracted this information from
figures using the same procedure explained in a recent systematic
review (28). Previous studies suggest that data extraction from
figures shows high precision and seems to be a useful option to
perform a meta-analysis when randomized clinical trials publish
figures as the only source of outcome data (29).
Because the correlation between pre- and post-scores is
required to impute the standard deviation within groups from
the standard deviation of the difference, this correlation needs toFrontiers in Psychiatry | www.frontiersin.org 4be known for calculating the confidence intervals in effect sizes
(30). As these correlations were not reported in studies, we
calculated different confidence intervals using different
estimated correlations (r = 0, r = 0.25, r = 0.5, r = 0.75). The
confidence intervals calculated with a correlation of 0.5 will be
included in a table in the article and the confidence intervals
calculated with different correlations (sensitivity analyses) will be
included in the supplementary material (Table S3).
Hedges’g and Cohen’s d are effect size measures that indicate
the standardized difference between two means. It is assumed that
0.2 can be considered a “small” effect size, 0.5 represents a
“medium” effect size and 0.8 a “large” effect size (31). In our
systematic review, as effect sizes represent changes in depressive
symptoms, positive effect sizes would imply mood improvement
(reduction in depressive scores after hormonal treatment) whereas
negative effect sizes would indicate mood worsening. Effect sizes
closer to zero correspond to hormonal treatments that were
relatively “neutral” in terms of changing the mood status.RESULTS
A total of 1,281 abstracts were identified, 1,257 in PubMed and
24 through other sources (www.clinicaltrials.gov). Further details
of the screening and selection process are described in Figure 1.FIGURE 1 | Flowchart for studies inclusion.May 2020 | Volume 11 | Article 479
González-Rodrı́guez et al. Psychopathology and Infertility TreatmentPublished Articles Reporting
Psychopathological Effects of Hormonal
Treatments Used for Infertility
Eight trials investigated the effects of hormones used in women
undergoing fertility treatments (2, 3, 32–37). All of them evaluated
the effect ofGnRHantagonists orGnRHagonists on the occurrence
of newly diagnosed depressive symptoms in women (Tables 1, 2
and 3). None of them explored the effects of ART onwomenwith a
previoushistoryof affectiveorpsychoticdisorders or theoccurrence
of psychotic or manic symptoms in women without a previous
diagnosis of mental disorder.
Haemmerli-Keller et al. (32) carried out a non-randomized trial
comparing women undergoing IVF with (cIVF) and without
gonadotropin stimulation (NC-IVF) (32). In the cIVF arm
(gonadotropin stimulation), human menopausal gonadotropin
(HMG) was initiated between days 3 and 5 of the menstrual
cycle, and GnRH antagonists were first administered
subcutaneously between days 6 and 7 of the menstrual cycle and
continued until ovulation induction with urinary human chorionicFrontiers in Psychiatry | www.frontiersin.org 5gonadotropin (hCG). NC-IVF patients received no stimulation at
all or very low dosages of clomiphene citrate from day 6 or 7 of the
menstrual cycle until the day of ovulation induction with hCG.
Depressive symptoms were evaluated in all women by means of
the Center for Epidemiologic Studies Depression Scale. The
authors found that patients who were given gonadotropin
stimulation showed higher rates of depression than women who
were not given gonadotropin stimulation.
Greco et al. (33) included 236 women who underwent
infertility treatment in a prospective controlled randomized
trial (33). Two methods of endometrial preparation for
blastocyst transfer were applied: modified natural cycle and
artificial cycle. Frozen-thawed single euploid blastocyst transfer
by means of a modified natural cycle was applied to 118 women.
The hormonal protocol for this treatment arm did not include
gonadotropin stimulation and final oocyte maturation was
induced with hCG. One hundred 18 women were included in
the artificial cycle arm. The hormonal protocol for this treatment
arm consisted of the administration of a GnRH agonistTABLE 1 | Main characteristics of published clinical trials reporting psychopathological complications with hormonal treatments for infertility (n=8).




Country Mean age (SD) or
Median [IQR]





Switzerland NC-IVF: 34.0 (7.2)
c-IVF: 34.9 (4.5)
Women between 18 and 42 years
with indication of IVF c-IVF or NC-
IVF depending on medical indication
and women’s wishes
Non-randomized trial:
a) c-IVF (IVF with HMG and GnRH antagonists) (n=62)
b) NC-IVF (IVF without gonadotropin stimulation) (n=57)





Women with indication of IVF at their
first IVF cycle
Randomized controlled trial, method of preparation,
blastocyst transfer:
a) modified natural cycle (n=118)
b) artificial protocol (n=118), GnRH agonist combined
with oestradiol valerate






Women from 12 sites in India, aged
18- 45 years undergoing for first
cycle of IVF/ICSI
Non-randomized trial:
a) Group A - GnRH antagonist (n=232)
b) Group B - GnRH agonist (n=460)
Stenbæk et al. (3) 83
women,




Women undergoing first infertility
treatment cycle of IVF or ICSI
Randomized trial:
a) GnRH antagonist (n=42): daily injections with r-FSH
b) GnRH agonist (n=41)
Bloch et al. (2) 108
women
Israel Total sample: 31.8
(5.4)
Women admitted, period 2006-2007,
first or second IVF cycle Age < 42
years No endometriosis No
psychopharmacological treatment
Prospective randomized trial:
a) Short protocol (GnRH agonist triptorelin plus daily r-
FSH (n=60) b) Long protocol (GnRH agonist triptorelin
for 14 days, followed by r-FSH (n=48)








Women who planned IVF,
randomization into one protocol No
previous history of unsuccessful IVF
Randomized controlled two-center trial:
a) Mild ovarian stimulation (GnRH antagonist co-
treatment) and single embryo transfer (n=197)
b) Standard GnRH agonist long-protocol ovarian
stimulation with double embryo transfer (n=194)








Women who planned IVF or
intracytoplasmatic sperm injection
with no previous IVF history
Randomized non-inferiority trial:
a) GnRH antagonist combined with single embryo
transfer (n=205)






Finland Goserelin: 33.6 (4.0)
Buserelin: 33.6 (3.8)
Women who planned IVF Randomized trial:
a) Long-acting s.c. goserelin (LHRH agonist) (n=49)
b) Buserelin acetate i.n. (LHRH agonist) (n=51) plus
150 IU of HMG/day after 11 days of GnRH-a treatmentAC, artificial cycle; GnRH-a, gonadotrophin-releasing hormone agonist; HADS, Hospital Anxiety and Depression Scale; HMG, human menopausal gonadotrophin; i.n., intranasal; c-IVF,
conventional in vitro fertilization; n-IVF, non-conventional in vitro fertilization; IQR, interquartile range; NC, natural cycle; LHRH, luteinizing hormone-releasing hormone; r-FSH, recombinant
follicle-stimulating hormone; s.c., subcutaneous; SD, standard deviation.May 2020 | Volume 11 | Article 479
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authors did not find statistically significant differences between
both groups in terms of anxiety and depressive symptoms,
neither before the beginning of treatment, nor on the following
days after progesterone administration, blastocyst transfer or at
the pregnancy test (33), suggesting that the use of GnRH agonists
show similar psychological effects compared to blastocyst
transfer in a modified natural cycle. However, when calculating
the effect sizes for longitudinal changes in depressive symptomsFrontiers in Psychiatry | www.frontiersin.org 6(Table 3), both treatment arms were associated with worsening
of depressive symptoms, although a greater negative effect was
seen in the protocol using GnRH agonists (g = -1.22) when
compared to the natural cycle protocol (g = -0.53), that did not
include gonadotropin stimulation. It is important to underscore
that mean (SD) HADS scores for both groups were below 7,
which suggests that depressive symptoms were mild, because a
cut-off score ≥ 8 is thought to be appropriate for detecting major
depression in the general practice (38).TABLE 2 | Methods and results of published clinical trials reporting psychopathological complications with hormonal treatments for infertility (n=8).
Author and year of
publication





To compare the psychological burden
of conventional IVF with gonadotropin








NC‐IVF patients had significantly lower
level of depression than cIVF patients.
Greco et al. (33) To evaluate clinical pregnancy rates of
two methods of endometrial
preparation for frozen-thawed single
euploid blastocyst transfer: modified
natural and artificial cycle with GnRH
agonist suppression






No significant differences were found
between both groups in anxiety and
depression scores before starting
treatment, on the days of progesterone
administration, at the blastocyst transfer,
and at the pregnancy test
Mamata et al. (34) To understand physical and
psychological burden in women under
fertility treatment
To compared GnRH antagonist
protocol with GnRH








No statistically significant differences were
found in physical or psychological burden
between the protocols (GnRH antagonist
and GnRH agonist)
Stenbæk et al. (3) To investigate whether women
exposed to GnRH agonist protocols
exhibit higher levels of mental distress
compared to women under GnRH
antagonist protocols







Although the GnRH antagonist protocol
was associated with mood fluctuations
during the stimulation phase, mood
disturbances were not induced by either
of the protocols
Bloch et al. (2) To determine whether affective
symptoms appear with the use of
GnRH agonists inducing hypogonadic
states during IVF cycles











states were not associated with increased
mood symptoms. Both protocols (short
and long) were comparable in their effects
on the induction of affective symptoms
de Klerk et al. (36) To compare the impact of
unsuccessful IVF on women’s
psychological symptoms between mild
and standard protocols
To compare self-reported symptoms
of depression between both protocols





At the first IVF treatment cycle, mild
ovarian stimulation (including GnRH
antagonists) was associated with fewer
short-term depressive symptoms than
conventional protocols
Heijnen et al. (35) To investigate whether mild and
standard protocols differ in the
proportion of term livebirths and
women’s well- being, and cost per
couple




Subjective Sleep Quality Scale
Differences in HADS




No statistically significant differences in
depressive or anxious symptoms between
the protocols
Tapanainen et al. (37) To investigate successful outcomes of
IVF treatment with goserelin depot
versus buserelin acetate
Ad hoc questionnaire with a
subjective estimation scale of
different side effects (e.g.,
tiredness, depression and
irritability) (scores from 1 =
absent to 5 = severe)
Mean (SD) scores after
treatment†
Buserelin group: higher incidence of
tiredness, depression, headache and
abdominal pain than the goserelin group.
No differences between the groups in
mental irritability, nausea, or swelling.†Effect sizes for the change (pre-post) in depressive symptoms for each treatment arm could be calculated (see Table 3).
CES-D, Center for Epidemiologic Studies Depression Scale; HSCL, Hopkins Symptom Checklist; HADS, Hospital Anxiety and Depression Scale; HMG, humanmenopausal gonadotrophin
(HMG); IVF, in vitro fertilization; NC-IVF, non-conventional in vitro fertilization; SD, standard deviation.May 2020 | Volume 11 | Article 479
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83 women undergoing treatment for infertility (3). Patients were
randomized to the GnRH antagonist protocol, which included
daily injections with r-FSH treatment, and GnRH agonists,
which were administered intranasally. Mood symptoms and
neuroticism traits were evaluated by self-reported assessment
scales. The authors found that neuroticism was associated with
higher scores on psychological distress, independent of the
protocol received. Mental distress associated with ART
treatments may not be attributed to hypogonadism or any
protocol (3). In terms of depressive symptoms, although
GnRH agonists seemed to show a slightly poorer profile than
GnRH antagonists, effect sizes were very small (Table 3), without
significant pre-post changes.
Similarly, Mamata et al. (34) carried out a trial across 12 IVF
centres in India (34). The authors divided participants into two
groups according to the type of treatment they received: a)
GnRH antagonists and b) GnRH agonists. Psychopathological
symptoms and somatic distress symptoms were assessed by
means of the Hospital Anxiety and Depression Scale (HADS)
and the Hopkins Symptom Check List (HSCL) during two
treatment visits. Although no statistically significant differences
in depressive or anxiety symptoms were found between both
protocol groups, the percentage of individuals who reportedFrontiers in Psychiatry | www.frontiersin.org 7depressive symptoms was higher in those receiving GnRH
agonists compared to those under GnRH antagonists,
suggesting that women undergoing IVF/ICSI may suffer from
higher depressive symptoms than women not undergoing these
treatments, irrespective of the protocol assigned.
With the main hypothesis that GnRH agonists may be
responsible for the induction of depressive symptoms in
women undergoing IVF, Bloch and co-workers (2) carried out
a prospective randomized trial with two main treatment groups:
a short protocol and a long protocol (2). The long protocol
consisted of the subcutaneous administration of the GnRH
agonist triptorelin for 14 days. 225 IU of recombinant FSH (r-
FSH) were administered in a second step. The short protocol was
defined by the administration of the GnRH agonist from the first
day of the cycle, followed by concomitant 225 IU r-FSH. The
authors hypothesized that a long protocol may induce prolonged
hypogonadism compared to a short protocol, a fact that may
increase levels of psychological distress and may be associated
with higher depressive symptoms (2). The authors found a
significant increase in depressive and anxiety symptoms during
IVF-ET cycles, which were higher between the hypogonadal
phase and the peak in gonadotropin stimulation, at later points
in treatment. The hypogonadal state which was GnRH agonist-
induced was not found to be associated with increased moodTABLE 3 | Effect sizes of changes in depressive symptoms in studies exploring the effect of hormonal treatments for infertility.





Mean SD Mean SD g d
95% CI limits
Haemmerli Keller et al.
(32)
CES-D NC-IVF
(no gonadotropin stimulation or very low
doses of clomiphene)
Pre (N = 57) 12.7 7.3 13.4 10.9 -0.07 -0.38 to 0.23
Post (N = 44)
CES-D cIVF
(HMG + GnRH antagonist)
Pre (N = 62) 12.2 8.6 15.7 7.9 -0.42 -0.73 to -0.12
Post (N = 45)
Greco et al. (33) HADS-D Modified-NC
(no gonadotropin stimulation;
oocyte maturation with hCG)
109 5.3 1.8 6.1 1.1 -0.53 -0.75 to -0.32
HADS-D Artificial cycle
(GnRH agonist)
113 4.9 1.5 6.8 1.6 -1.22 -1.47 to -0.98
Mamata et al. (34)§ HADS-D GnRH antagonist 232 -0.1 3.6 -0.03 NA#
HADS-D GnRH agonist 460 0.1 3.7 0.03 NA#
Stenbæk et al. (3)† MDI GnRH antagonist 42 8.7 9.6 8.2 7.3 0.06 -0.25 to 0.37
MDI GnRH agonist 41 6.3 3.8 7 5.4 -0.15 -0.47 to 0.17
Bloch et al. (2) CES-D Long-protocol
(GnRH agonist for 14 days+ r-FSH)
48 32.5 7.6 36.2 9.4 -0.43 -0.073 to -0.13
CES-D Short- protocol
(GnRH agonist + r-FSH from first day of
the cycle)
60 30.6 8.5 34.3 9.7 -0.40 -0.67 to -0.14









51 1.35 0.87 1.59 1.04 -0.25 -0.53 to 0.03May 2020 | Volumeg, Hedges’ g; d, Cohen’s d; SD, standard deviation; CI, confidence intervals; CES-D, Center for Epidemiologic Studies Depression Scale; cIVF, in vitro fertilization with gonadotropin
stimulation; AC, artificial cycle; NC, natural cycle; NC-IVF, in vitro fertilization without gonadotropic stimulation; GnRH, gonadotropin- releasing hormone; HMG, human menopausal
gonadotropin; r-FSH, recombinant follicle-stimulating hormone; HADS-D, Hospital Anxiety and Depression Scale—depression subscore; MDI, Major Depression Inventory; NA, not
assessed.
§In the Mamata et al. (34) study, mean differences in HADS-D were reported. Hedges g’ was calculated taking into account this information.
†As median and interquartile range were reported in the study by Stenbæk et al. (3), mean (SD) was computed as suggested by Wan et al.
‡In the Tapanainen et al. (37) study, mean (SD) changes in subjective symptoms of depression were obtained from figures with t he procedure described by Labad et al. (28).
#d Cohen confidence interval limits were not calculated because means and standard deviations for baseline and final visits were not available.11 | Article 479
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correlated with an increase in depression. Effect sizes for the
change in depressive symptoms suggest that both protocols are
associated mild mood worsening (Table 3).
De Klerk et al. (36) investigated the psychopathological effect
of IVF treatment on women undergoing mild ovarian
stimulation (including GnRH antagonist and single embryo
transfer) compared to an standard strategy (long-protocol with
GnRH agonist and double embryo transfer) (36). After IVF
treatment, women with negative outcome were more likely to
present depressive symptoms 1 week after the end of treatment
compared to women who received mild IVF treatment. The
prevalence of possible depressive disorder (defined as a HADS
score>7) was 38.8% for the women in the standard IVF group
who underwent multiple IVF cycles against 19.4% of the women
in the mild IVF group (p = 0.04). The authors associated these
results with the prolonged ovarian suppression by GnRH
agonists in those women who underwent the standard IVF,
suggesting that these treatments may lead to more symptoms
of depression.
Heijnen et al. (35) carried out a randomized, open-label, non-
inferiority trial in 404 women with an indication for IVF or ICSI
in the Netherlands, of whom 205 received mild ovarian
stimulation (single embryo transfer with the administration of
GnRH antagonists) and 199 were given standard ovarian
stimulation with the transfer of two embryos and with the
administration of GnRH agonists (35). The authors assessed
depressive symptoms and anxiety by means of the HADS and
found no statistically significant differences in psychopathological
symptoms between both groups (35).
One of the most relevant studies was the randomized trial
carried out by Tapanainen et al. (37). In this IVF study, patients
received two types of GnRH agonists. Individuals were
randomized to treatment with long-acting subcutaneous
goserelin or with intranasally administered buserelin acetate.
They both stimulate the production of testosterone and
oestrogen in a non-pulsatile manner, which results in the
downregulation of both sex hormone systems (37). After 11
days of the administration of either goserelin or buserelin, the
administration of 150 IU of HMG/day was started. The authors
found that patients receiving buserelin reported more depressive
mood, tiredness, and headache 1 week after starting the GnRH
agonist, when compared to those treated with goserelin (37).
However, when considering the effect sizes for the change in
depressive symptoms during the study, both protocols had
similar effects (mild worsening) on mood (Table 3).
Non-Published Studies Designed to
Assess Psychopathology in Women
Receiving Hormonal Treatments for
Infertility (Completed or Ongoing)
One trial was registered at clinicaltrials.gov and reported to
be completed.
In 2010, Pittman et al. started a double-blind, placebo-
controlled, crossover clinical trial in 20 menstruating womenFrontiers in Psychiatry | www.frontiersin.org 8with regular menstrual cycles who suffered from unexplained
infertility (39). The main goal of this trial was to explore
psychopathological symptoms and physical concerns in women
receiving clomiphene citrate for superovulation with intrauterine
insemination. Women were randomized to treatment with
clomiphene citrate or placebo and received this intervention on
days 3–7 of their menstrual cycle. Ten patients received
clomiphene citrate 50 mg daily and then placebo daily, and 10
women received placebo and then clomiphene citrate daily.
Physical, behavioral, and mental symptoms were explored by
using the following assessment scales: Follicular Cycle Total
Physical Score for the Calendar of Premenstrual Experiences
(COPE) self-assessment, the Follicular Cycle Total Behavioral
Score for the Calendar of Premenstrual Experiences (COPE) self-
assessment, the Luteal Cycle Total Behavioral Score for the
Calendar of Premenstrual Experiences (COPE) self-assessment
and the Luteal Cycle Total Physical Score for the Calendar of
Premenstrual Experiences (COPE) self-assessment. Although
not statistically relevant, patients receiving placebo showed
higher scores than those receiving clomiphene citrate on the
Follicular Cycle Behavioral and Physical Scores (COPE). No
other differences in median scores were found in behavioral,
mental, and physical symptoms as measured by the luteal scales.Quality Assessment and Risk of Bias
The assessment of the risk of bias has been presented in detail in
Table S2. Of all nine clinical trials included in our systematic
review, four were considered to be good (2, 3, 36, 39), four fair
(33–35, 37), and only one (32) had poor quality.
We did not identify any trial publication or non-publication
of results regarding the occurrence of psychotic symptoms in
women undergoing fertility treatments.DISCUSSION
In this paper, we carried out a systematic review on available
work on the psychopathological effects of hormonal treatments
for infertility on women and the effects of these therapies on the
occurrence of newly diagnosed mood and psychotic disorders.
Finally, nine trials were included, all of them in non-clinical
populations. Four trials compared GnRH agonists and GnRH
antagonists (3, 34–36), showing a better mood profile (less
depressive symptoms) for those hormonal protocols including
antagonists in one trial. Two trials compared protocols using
either GnRH agonists or GnRH antagonists versus natural cycle
protocols that did not use gonadotropin stimulation, reporting a
better mood profile in those protocols without gonadotropin
stimulation (32, 33). Other two studies comparing long and short
protocols of GnRH agonists (2) and two GnRH agonists
(buserelin and goserelin) (37) did not find significant
differences in mood changes between treatment arms. An
unpublished study compared two patterns of clomiphene vs
placebo administration with no differences between groups (39).May 2020 | Volume 11 | Article 479
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GnRH antagonists or GnRH agonists on the occurrence of newly
diagnosed depressive disorder or depressive symptoms for the first
time in women. None of them investigated the risk or prevalence of
relapses in women with a previous diagnosis of depressive disorders
or psychotic disorders. When focusing on hormonal compounds
other than GnRH agonists or antagonists, one recent trial has been
developed to study the effect of clomiphene citrate on women under
the IVF protocol (39). Moreover, in the study by Haemmerli Keller
et al. (32), patients under the protocol without gonadotropin
stimulation could receive low doses of clomiphene (32). This
latter study suggests that the lack of gonadotropin stimulation is
associated with fewer changes in mood, as the effect size was very
small (g = -0.07).
Celano et al. (40) and Wilkins and collaborators (41) pointed
out that GnRH agonists (e.g., leuprolide and goserelin) induce
hypogonadism (40, 41), which could be related to different
psychiatric side effects. In the information about these
hormonal drugs (42, 43), depressive symptoms also seem to be
reported. These findings have been replicated in subsequent case
series (44, 45) and retrospective studies, including the report of a
patient treated with leuprolide (46). Furthermore, prophylactic
treatment with SSRIs has been reported to prevent the
development of depressive symptoms in these patients (45).
In our systematic review, we found that patients receiving
ovarian stimulation with GnRH antagonists had increased
depressive symptoms compared to patients who did not
receive ovarian stimulation (32). One study suggested that
treatment with one GnRH agonist, buserelin, had a poorer
mood profile than other GnRH agonist (goserelin) 1 week later
but showed similar mood changes at the end of the trial (37).
However, GnRH agonists did not seem to differ from GnRH
antagonists in their associated occurrence of depressive
symptoms, suggest ing that nei ther protocol has a
psychopathological effect on women undergoing fertility
treatments (3, 34–36).
In contrast, Ben Dor et al. (47) studied the effect of GnRH
agonists on a sample of 72 healthy women (medication-free; not
pregnant; no significant past or current medical illness; reported
regular menstrual cycles; and normal physical, gynaecological
examinations, and laboratory results) (47). The absence of
current or past Axis I psychiatric illness was confirmed by
Structured Clinical Interview for DSM-IV. The objective of the
study was to better understand whether the acute induction of
hypogonadism may determine significant depressive symptoms
in healthy premenopausal women, which individual symptoms
may be associated with hypogonadism and increase susceptibility
to depression and whether changes in plasma levels of ovarian
hormones correlate with changes in mood symptoms (47). After
a 2-month screening phase, every woman received the first dose
of depot leuprolide acetate. Relative to baseline, induced
hypogonadism with GnRH agonist was associated with
significantly decreased sexual interest, disturbed sleep, and hot
flashes but no significant change in any mood-related symptom
scores (47). The authors proposed that depressive symptomsFrontiers in Psychiatry | www.frontiersin.org 9associated with GnRH agonist ovarian suppression in
menopause could reflect mainly the effects of ovarian
suppression on women who are more vulnerable to the
development of depression or who are currently depressed
(47). However, once again, no clinical trials have explored the
effect of leuprolide on women undergoing fertility treatments.
Bloch and collaborators (2) investigated the relationship
between affective symptoms and gonadal steroids during in
vitro fertilization (2). They found that the drop from high
oestradiol levels at the oestradiol phase to lower levels at the
progesterone phase was correlated with increasing depressive
symptoms, suggesting that the abrupt decline in oestrogen levels
can precipitate negative mood states. This fact may be
responsible for the variability of the presence of depressive
symptoms in women undergoing IVF (2). This may be
partially in line with some observational studies exploring the
prevalence of depressive symptoms in women undergoing
fertility treatments. Particularly, Volgsten and co-workers (22)
carried out an observational study including couples undergoing
IVF or ICSI and applied the Primary Care Evaluation of Mental
Disorders (PRIME-MD) system, which is a tool to evaluate the
prevalence of psychiatric disorders according to 2% in men,
being major depression the most commonly found, irrespective
of the hormonal compound they received. More recently, other
studies have reported that pregnant women after fertility
treatment did not differ in terms of depressive symptoms
compared to those naturally pregnant, suggesting that the
treatment did not have a negative impact on mood (23).
However, the hormonal compounds were not included in the
discussion. Evans-Hoeker et al. (48) carried out a cohort study
including participants in two previous randomized trials, namely
PPCOS II and AMIGOS (48). The first trial compared patients
treated with clomiphene citrate versus letrozole, and the second
compared gonadotropins, clomiphene citrate and letrozole. Both
studies assessed whether maternal depression would have an
influence on pregnancy outcomes after non-IVF fertility
therapies. They did not find any negative effect of current
active depression on non-IVF outcomes. The effect of
hormonal compounds used in fertility treatment on the
recurrence of major depression have been poorly investigated.
Sejbaek et al. (49) carried out a register-based national cohort
study including women undergoing IVF, ICSI, and other embryo
transfer treatments (49). Women with a previous diagnosis of
depression had lower rates of live births. The authors did not find
statistically significant differences in rates of depression, but they
recommended that women with previous depression may
require specific psychiatric attention before starting a new
treatment. In the same line, other authors highlight that a
history of major depression would be a significant predictor
for major depression during fertility treatment (50). Psychosocial
support and interventions addressed to women with a previous
history of depression have been recommended when initiating
infertility treatment.
We did not find any clinical trial specifically investigating the
effects of hormonal treatments on depressive symptoms inMay 2020 | Volume 11 | Article 479
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observational study that included women receiving infertility
treatments with a history of major depressive disorder or bipolar
disorder (24), a high risk of depressive relapse was found, even in
those women maintaining psychotropic medication. These
results suggest that maintenance of medication is not sufficient
to avoid affective relapses. In our systematic review, we did not
find clinical trials assessing recurrences in patients with
affective disorders.
Women with polycystic ovary syndrome (PCOS) show an
increased prevalence of higher depression and anxiety scores and
increased odds of moderate and severe depressive and anxiety
symptoms compared with controls (51). On the other hand, a
few studies that have evaluated the impact of PCOS-related
treatments (lifestyle interventions and pharmacotherapy) on
mood have reported no detrimental effect or even some
improvement in depressive and anxiety symptoms and quality
of life (51). In addition, clomiphene citrate, a selective oestrogen
receptor modulator used to induce ovulation, even in patients
with PCOS, has been associated with mood lability and
depressed mood in two cross-sectional studies (52, 53). In the
cross-sectional, self-report survey of Choi et al. (53), 41% of
clomiphene-treated women experienced depressed mood, and 75
of 162 (45%) experienced mood swings during treatment (53).
Mood changes (54), suicidal behavior (55), and visual
hallucinations (56) have also been associated with clomiphene
treatment in case reports.
None of the selected published clinical trials in our systematic
review specifically investigated the psychopathological effects of
the use of clomiphene citrate in the treatment of infertility on
women. In an unpublished randomized double-blind crossover
trial in 20 women (53), clomiphene treatment was not associated
with mood or behavioral changes, a result that contrasts those of
other studies suggesting that clomiphene induces psychological
side effects quite frequently (53).
In relation to patients with psychotic disorders, to the best of our
knowledge, no clinical trials have evaluated the psychopathological
effects of hormonal treatments for infertility on women diagnosed
with bipolar disorder, schizophrenia, or other psychotic disorders.
A case report linked the use of leuprolide acetate for in vitro
fertilization (IVF) treatment to a psychotic exacerbation in a 37-
year-old woman who suffered from a previous schizoaffective
psychosis (57). In this line, a case series of Purvin (58) showed
different visual disturbances (some of them persistent) secondary to
clomiphene citrate treatment in three women treated for infertility
with clomiphene for 4 to 15 months (58). In a review by Seeman
(59), there were five case reports of a self-limited psychotic disorder
induced by clomiphene (59). All cases were reported to start
psychotic symptoms during treatment, to have a paranoid
component and to stop when the drug was withdrawn. We did
not find any trial reporting the potential effects of hormones used in
fertility treatments on women with psychosis or the occurrence of
psychotic symptoms in non-diagnosed women. However, some
case reports have been reported on the use of clomiphene. A recent
national register study compared success rates of fertility treatmentsFrontiers in Psychiatry | www.frontiersin.org 10in women with and without psychotic disorders prior to the
treatment (25), as a part of a cohort of 42,915 Danish women
undergoing fertility treatments. Women with previous diagnosis of
psychotic disorder had lower rates of success compared to non-
psychotic women. The authors did not evaluate depressive
symptoms as the main outcomes.
Several limitations in this systematic review should be
considered. The most important limitation of this systematic
review is the absence of a sufficient number of published articles
on the psychopathological effects of hormone compounds used
in infertility treatments in women. Furthermore, most clinical
trials included in our systematic review excluded patients with a
psychiatric history or psychopathological treatment. Therefore,
these exclusion criteria might bias the evidence because most
studies excluded women with mental illnesses. Although the
quality of selected clinical trials was fair to good in most cases (8/
9 = 89%), as none of them included patients with serious mental
illnesses, the research field needs to conduct more inclusive
clinical trials to overcome this limitation.
The prediction of acute exacerbations or the occurrence of
newly diagnosed mental disorders is limited by the scarce
literature in the field. Furthermore, most studies were focused
on depressive or anxiety symptoms, and they did not assess, in
general, psychopathological symptoms according to the most
commonly used assessment scales for depression. Several
authors have reported that psychotic symptoms may occur
during fertility treatments, during or after the use of hormone
compounds; however, to date, few studies have focused on patients
suffering from schizophrenia and other psychotic disorders. Most
of them are case reports or case series, and trials are still lacking on
this topic. To the best of our knowledge, this is the first systematic
review on the psychopathological effects of hormonal treatments
for infertility. Although the number of selected clinical trials was
low, our systematic review opens new avenues on the investigation
of hormone effects in women undergoing infertility treatments.
Future studies need to include patients with major mood and
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González-Rodrı́guez et al. Psychopathology and Infertility TreatmentACKNOWLEDGMENTS
JL received an Intensification of the Research Activity Grant
(SLT006/17/00012) from the Health Department of the
Generalitat de Catalunya.Frontiers in Psychiatry | www.frontiersin.org 11SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online
at: https://www.frontiersin.org/articles/10.3389/fpsyt.2020.
00479/full#supplementary-materialREFERENCES
1. Rooney KL, Domar AD. The relationship between stress and infertility.
Dialogues Clin Neurosci (2018) 20:41–7.
2. Bloch M, Azem F, Aharonov I, Ben Avi I, Yagil Y, Schreiber S, et al. GnRH-
agonist induced depressive and anxiety symptoms during in vitro
fertilization-embryo transfer cycles. Fertil Steril (2011) 95:307–9.
doi: 10.1016/j.fertnstert.2010.07.1073
3. Stenbæk DS, Toftager M, Hjordt LV, Jensen PS, Holst KK, Bryndorf T, et al.
Mental distress and personality in women undergoing GnRH agonist versus
GnRH antagonist protocols for assisted reproductive technology. Hum
Reprod (2015) 30:103–10. doi: 10.1093/humrep/deu294
4. Stanhiser J, Steiner AZ. Psychosocial Aspects of Fertility and Assisted
Reproductive Technology. Obstet Gynecol Clin North Am (2018) 45:563–74.
doi: 10.1016/j.ogc.2018.04.006
5. Hanson B, Johnstone E, Dorais J, Silver B, Peterson CM, Hotaling J. Female
infertility, infertility-associated diagnoses, and comorbidities: a review. J Assist
Reprod Genet (2017) 34:167–77. doi: 10.1007/s10815-016-0836-8
6. Santos C, Sobral MP, Martins MV. Effects of life events on infertility
diagnosis: comparison with presumably fertile men and women. J Reprod
Infant Psychol (2017) 35:1–13. doi: 10.1080/02646838.2016.1249834
7. Briceag I, Costache A, Purcarea VL, Cergan R, Dumitru M, Briceag I, et al.
Fallopian tubes–literature review of anatomy and etiology in female infertility.
J Med Life (2015) 8:129–31.
8. Chambers GM, Harrison C, Raymer J, Petersen Raymer AK, Britt H,
Chapman M, et al. Ledger W5, Norman RJ6. Infertility management in
women and men attending primary care-patient characteristics, management
actions and referrals. Hum Reprod (2019) 34:2173–83. doi: 10.1093/humrep/
dez172
9. Lunenfeld B, Bilger W, Longobardi S, Alam V, D’Hooghe T, Sunkara SK. The
Development of Gonadotropins for Clinical Use in the Treatment of
Infertility. Front Endocrinol (Lausanne) (2019) 10:429. doi: 10.3389/
fendo.2019.00429
10. Niederberger C, Pellicer A. Introduction: IVF’s 40th world birthday. Fertil
Steril (2018) 110:4. doi: 10.1016/j.fertnstert.2018.05.017
11. Bai F, Wang DY, Fan YJ, Qiu J, Wang L, Dai Y, et al. Assisted reproductive
technology service availability, efficacy and safety in mainland China: 2016.
Hum Reprod (2020) 35:446–52 doi: 10.1093/humrep/dez245
12. Ray A, Shah A, Gudi A, Homburg R. Unexplained infertility: an update and
review of practice. Reprod Biomed Online (2012) 24:591–602. doi: 10.1016/
j.rbmo.2012.02.021
13. Lai Q, Zhang H, Zhu G, Li Y, Jin L, He L, et al. Comparison of the GnRH agonist
and antagonist protocol on the same patients in assisted reproduction during
controlled ovarian stimulation cycles. Int J Clin Exp Pathol (2013) 6:1903–10.
14. Toftager M, Bogstad J, Bryndorf T, Løssl K, Roskær J, Holland T, et al. Risk of
severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH
agonist protocol: RCT including 1050 first IVF/ICSI cycles. Hum Reprod
(2016) 31:1253–64. doi: 10.1093/humrep/dew051
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